Data for: Global frequency analyses of canine progressive rod-cone degeneration–progressive retinal atrophy and collie eye anomaly using commercial genetic testing data

Hundreds of genetic variants associated with canine traits and disorders have been identified, with commercial tests offered. However, the geographic distributions and changes in allele and genotype frequencies over prolonged, continuous periods of time are lacking. This study utilized a large set of genotypes from dogs tested for the progressive rod-cone degeneration–progressive retinal atrophy (prcd-PRA) G>A missense PRCD variant (n = 86,667) and the collie eye anomaly (CEA)-associated NHEJ1 deletion (n = 33,834) provided by the commercial genetic testing company (Optigen/Wisdom Panel, Mars Petcare Science & Diagnostics). These data were analyzed using the chi-square goodness-of-fit test, time-trend graphical analysis, and regression modeling in order to evaluate how test results changed over time. The results span fifteen years, representing 82 countries and 67 breeds/breed mixes. Both diseases exhibited significant differences in genotype frequencies (p = 2.7 × 10−152 for prc..., Data for this study comprised genotype status for prcd-PRA (n=86,667 dogs) and CEA (n=33,834 dogs) tested by a commercial genetic testing company (OptiGen, LLC acquired by Mars Petcare in 2018) between the years 2004-2019. These data underwent statistical analysis (Chi-square goodness-of-fit, logistic regression modeling, multinomial regression modeling) to determine significance of changing allele and genotype frequencies over time as well as the impact of dog breed, geography, progress of time, and popularity on overall likelihood of a dog developing either disease or having a carrier status., , # Genotype and sample data from Clark et al. \"Global Frequency Analyses of Canine Progressive Rod-Cone Degeneration–Progressive Retinal Atrophy and Collie Eye Anomaly Using Commercial Genetic Testing Data\"

## Description of the data and file structure

Genotype and metainformation for domestic dog samples that were owner-submitted to commercial genetic testing companies OptiGen, LLC and Mars Petcare between the years of 2004-2019.

In total, there were 86,667 samples tested for Progressive Rod-Cone Degeneration-Progressive Retinal Atrophy (prcd-PRA) and 33,834 samples tested for Collie Eye Anomaly (CEA), both diseases prevalent across different dog breeds and with an effect on canine eyesight.

Data file: Clark2023_Dataset.xlsx

Data is provided as an .xlsx file with two spreadsheets of similar arrangement - one for CEA and one for prcd-PRA samples. Each row on the table represents anonymized samples while columns represent variables:

*Sample: number assigned to distinguish samples ...